Chemoradiotherapy for locally advanced pancreatic cancer
Mené sur 74 patients atteints d'un cancer du pancréas de stade localement avancé (âge : 18 ans et plus), cet essai multicentrique de phase II compare l'efficacité, du point de vue de la survie sans progression à 9 mois, et la toxicité de deux protocoles de chimioradiothérapie, l'un à base de gemcitabine et l'autre à base de capécitabine
Pancreatic cancer is a devastating disease, characterised by a poor prognosis. 1 The need for further research to improve surgery, radiation oncology, and systemic approaches is clear, and all relevant research, whether basic science or a multicentre clinical trial, is most welcome. Few randomised trials are done in pancreatic cancer, and the substantial effort involved in such studies should be acknowledged. ..
The Lancet Oncology , commentaire, 2012